Skip to main content

FDA Approvals

FDA Approvals
Enfortumab Vedotin Promising Third-Line Option for Metastatic Urothelial Cancer
Phoebe Starr
Phoebe Starr
Read More
FDA Approvals
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma
Wayne Kuznar
Read More
FDA Approvals
Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors
Wayne Kuznar
Wayne Kuznar
Read More
FDA Approvals
Darzalex Combined with Revlimid and Dexamethasone New First-Line Regimen for Patients with Multiple Myeloma Ineligible for Transplant
Read More
FDA Approvals
Keytruda Receives New Indication for Metastatic Small-Cell Lung Cancer After Disease Progression
Read More
FDA Approvals
Keytruda First PD-1 Inhibitor Approved as First-Line Monotherapy for Patients with Metastatic or Unresectable Head and Neck Cancer
Read More
FDA Approvals
Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma
Read More
FDA Approvals
Xpovio Receives FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
Read More
FDA Approvals
Eylea (Aflibercept), a VEGF Receptor Inhibitor, Receives New Indication for All Stages of Diabetic Retinopathy
Lilly Ostrovsky
Lilly Ostrovsky
Read More
Page 20 of 53
Results 191 - 200 of 524